{
    "relation": [
        [
            "",
            "CP-690,550 5 mg",
            "CP-690,550 10 mg",
            "Placebo, Then CP-690,550 5 mg",
            "Placebo, Then CP-690,550 10 mg"
        ],
        [
            "Description",
            "CP-690,550 5 mg tablet orally twice daily up to Month 6.",
            "CP-690,550 10 mg tablet orally twice daily up to Month 6.",
            "Placebo matched to CP-690,550 tablet orally twice daily up to Month 3 followed by CP-690,550 5 mg tablet orally twice daily up to Month 6.",
            "Placebo matched to CP-690,550 tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily orally up to Month 6."
        ]
    ],
    "pageTitle": "Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00960440?sect=Xp15&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042989301.17/warc/CC-MAIN-20150728002309-00024-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 863122383,
    "recordOffset": 863109838,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups No text entered. Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. Population Description \u00a0 Hide Baseline Characteristics \u00a0 Baseline Characteristics \u00a0 Show Participant Flow \u00a0 Participant Flow Drug: CP-690,550 Drug: Placebo Interventions: Arthritis, Rheumatoid Condition: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety/Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Double\u00a0Blind\u00a0(Subject,\u00a0Caregiver,\u00a0Investigator,\u00a0Outcomes\u00a0Assessor); \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study Design: Interventional Study Type: Results First Received: December 6, 2012 \u00a0",
    "textAfterTable": "Total Total of all reporting groups Baseline Measures \u00a0 \u00a0 CP-690,550 5 mg \u00a0 \u00a0 CP-690,550 10 mg \u00a0 \u00a0 Placebo, Then CP-690,550 5 mg \u00a0 \u00a0 Placebo, Then CP-690,550 10 mg \u00a0 \u00a0 Total \u00a0 Number of Participants \u00a0 [units:\u00a0participants] \u00a0 133 \u00a0 \u00a0 134 \u00a0 \u00a0 66 \u00a0 \u00a0 66 \u00a0 \u00a0 399 \u00a0 Age \u00a0 [units:\u00a0years] Mean (Standard Deviation) \u00a0 55.4 \u00a0(11.5) \u00a0 \u00a0 55.1 \u00a0(11.3) \u00a0 \u00a0 54.3 \u00a0(11.7) \u00a0 \u00a0 54.5 \u00a0(11.0) \u00a0 \u00a0 55.0 \u00a0(11.3) \u00a0 Gender \u00a0 [units:\u00a0participants] \u00a0 \u00a0 \u00a0",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}